- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02432833
Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients (STEADY)
April 12, 2018 updated by: Chiesi Farmaceutici S.p.A.
The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Multicentre, Open label, Randomized, Two-arm, parallel-group study to assess efficacy and safety of Envarsus® compared with tacrolimus used as per current clinical practice in the initial maintenance setting in de novo kidney transplant patients.
The study will be conducted in approximately 10 european countries.
Study Type
Interventional
Enrollment (Actual)
428
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Parma, Italy, 43123
- Chiesi farmaceutici Spa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient's signed informed consent obtained prior to any study-related procedure;
- Adult men and women at least 18 years of age with end-stage renal disease who are recipients (or will be recipients) of a kidney transplant from a living or deceased donor;
- No known contraindications to the administration of tacrolimus, other macrolides and study drugs excipients;
- Patients must agree to use a highly reliable method of birth control;
- Donor-recipient negative cross match test, and compatible AB0 blood type;
- Able to swallow tablets and capsules
Exclusion Criteria:
- Recipient of any transplanted organ other than kidney;
- Recipient of a previous renal transplant;
- Recipient of a kidney from a donor after cardiac death;
- Recipient of a kidney from an AB0 incompatible or positive cross-match donor;
- Current (not older than 3 months) anti-HLA Panel Reactive Antibody (PRA) levels higher than 30%. Whenever PRA, either complement-dependent cytotoxicity-PRA or calculated PRA , is not available, patients who are positive on solid-phase screening assay for anti-HLA antibodies must not be enrolled;
- Recipient of a kidney with a cold ischemia time of ≥ 30 hours;
- White blood cells count ≤ 2.8x109 cells/L unless ANC >1.0x109/L;
- Platelet count < 50 x109 cells/L;
- ALT or AST levels >3 times the normal upper limit during the 30 days prior transplant procedure;
- Current abuse of drugs or alcohol;
- Incapable of understanding purpose and risk of study, unable to give written informed consent or unwilling to comply with study protocol;
- Treatment with any other investigational agent in the 30 days prior to enrolment;
- Kidney recipients and/or donors positive for HCV (HCV-RNA positive or HCV-Ab positive respectively);
- Kidney recipients and/or donors positive for HBV (HBV-DNA or HBS-Ag positive);
- Recipients positive for HIV;
- Patient or donor with current diagnosis or history of malignancy within the past 5 years except basal or non-metastatic squamous cell carcinoma of the skin successfully treated;
- Uncontrolled concomitant infection, systemic infection requiring treatment or any other unstable condition that could interfere with study objectives;
- Severe diarrhoea, vomiting, active peptic ulcer or GI disorder that may affect absorption of tacrolimus;
- Known hypersensitivity to tacrolimus other macrolides and study drugs excipients;
- Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS are willing to use reliable methods of contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Envarsus® (tacrolimus)
prolonged-release tablets once daily and orally
|
Envarsus® tablets, once daily, oral formulation.
Prolonged -release formulation of tacrolimus
|
Active Comparator: Prograf or Advagraf
Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
|
Prograf® hard capsules, twice daily, oral formulation
Advagraf® prolonged-release hard capsules, once daily, oral formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tacrolimus total daily dose (TDD) from week 3 to month 6
Time Frame: from week 3 to month 6
|
from week 3 to month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tacrolimus blood trough level (TL).
Time Frame: from screening to months 6
|
from screening to months 6
|
number of dose adjustment
Time Frame: from screening to months 6
|
from screening to months 6
|
Occurrence of treatment failure
Time Frame: from screening to months 6
|
from screening to months 6
|
Delayed graft function
Time Frame: from screening to months 6
|
from screening to months 6
|
Acute rejection requiring treatment
Time Frame: from screening to months 6
|
from screening to months 6
|
Consumption of concomitant immunosuppressant medications
Time Frame: from screening to months 6
|
from screening to months 6
|
Treatment discontinuation
Time Frame: from screening to months 6
|
from screening to months 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Klemens Budde, MD, Berlin, Germany
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
January 24, 2017
Study Completion (Actual)
January 24, 2017
Study Registration Dates
First Submitted
April 29, 2015
First Submitted That Met QC Criteria
May 1, 2015
First Posted (Estimate)
May 4, 2015
Study Record Updates
Last Update Posted (Actual)
April 13, 2018
Last Update Submitted That Met QC Criteria
April 12, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCD-06235AA1-01
- 2014-004314-29 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Iperboreal Pharma SrlWithdrawnEnd-Stage Renal Disease
-
Cubist Pharmaceuticals LLCCompleted
-
Medical University of GrazWithdrawnEnd-stage Renal DiseaseAustria
-
Janssen Research & Development, LLCBayerCompleted
-
Chulalongkorn UniversityCompletedEnd-stage Renal DiseaseThailand
-
University of KansasCompletedEnd-Stage Renal Disease
-
Eisai Co., Ltd.CompletedEnd-Stage Renal DiseaseJapan
Clinical Trials on ENVARSUS®
-
Methodist HealthcareCompletedRecipients of Liver TransplantUnited States
-
Yale UniversityVeloxis PharmaceuticalsRecruitingKidney Transplant; ComplicationsUnited States
-
Chiesi Farmaceutici S.p.A.CompletedOrgan or Tissue Transplant; ComplicationsFrance
-
University Hospital, LimogesUnknown
-
Hospital Universitari de BellvitgeCompleted
-
University Hospital, EssenRecruitingPediatric Kidney DiseaseGermany
-
Georgetown UniversityTerminatedRenal Transplant RecipientsUnited States
-
University Hospital TuebingenCompletedPosttransplant Diabetes MellitusGermany
-
University of MinnesotaCompletedKidney Transplant Failure and RejectionUnited States
-
University of BrasiliaMinistry of Health, BrazilCompletedCutaneous LeishmaniasisBrazil